Concepts (245)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Schistosoma mansoni | 25 | 2026 | 26 | 2.610 |
Why?
|
| Thioredoxin-Disulfide Reductase | 8 | 2026 | 8 | 1.710 |
Why?
|
| Enzyme Inhibitors | 10 | 2026 | 47 | 1.460 |
Why?
|
| Cryptosporidium parvum | 2 | 2026 | 2 | 1.140 |
Why?
|
| Animals | 39 | 2026 | 1050 | 1.060 |
Why?
|
| NADH, NADPH Oxidoreductases | 11 | 2026 | 11 | 0.980 |
Why?
|
| Multienzyme Complexes | 11 | 2026 | 12 | 0.980 |
Why?
|
| Cryptosporidium | 1 | 2025 | 1 | 0.900 |
Why?
|
| Protozoan Proteins | 1 | 2025 | 1 | 0.900 |
Why?
|
| Antimalarials | 5 | 2026 | 6 | 0.850 |
Why?
|
| Oxidation-Reduction | 9 | 2026 | 13 | 0.760 |
Why?
|
| Schistosomiasis mansoni | 9 | 2022 | 10 | 0.720 |
Why?
|
| Auranofin | 6 | 2025 | 6 | 0.640 |
Why?
|
| Peroxiredoxins | 8 | 2021 | 8 | 0.620 |
Why?
|
| Naphthoquinones | 4 | 2024 | 4 | 0.620 |
Why?
|
| Antineoplastic Agents | 3 | 2025 | 16 | 0.610 |
Why?
|
| Schistosomicides | 5 | 2026 | 5 | 0.600 |
Why?
|
| Humans | 22 | 2026 | 2957 | 0.580 |
Why?
|
| NADP | 4 | 2024 | 5 | 0.500 |
Why?
|
| Gold | 3 | 2026 | 3 | 0.500 |
Why?
|
| Anthelmintics | 4 | 2020 | 6 | 0.480 |
Why?
|
| Models, Molecular | 7 | 2026 | 19 | 0.470 |
Why?
|
| Schistosomiasis | 3 | 2023 | 4 | 0.460 |
Why?
|
| Thioredoxin Reductase 1 | 2 | 2025 | 2 | 0.450 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2025 | 4 | 0.450 |
Why?
|
| Hypertension, Pulmonary | 2 | 2026 | 4 | 0.440 |
Why?
|
| Plasmodium falciparum | 4 | 2026 | 4 | 0.430 |
Why?
|
| Mice | 11 | 2026 | 343 | 0.410 |
Why?
|
| Peroxidases | 2 | 2006 | 3 | 0.400 |
Why?
|
| Coordination Complexes | 2 | 2026 | 2 | 0.400 |
Why?
|
| Crystallography, X-Ray | 6 | 2026 | 8 | 0.390 |
Why?
|
| Glutathione | 4 | 2025 | 4 | 0.300 |
Why?
|
| Thioredoxins | 3 | 2025 | 3 | 0.290 |
Why?
|
| Molecular Sequence Data | 12 | 2013 | 31 | 0.290 |
Why?
|
| Drug Evaluation, Preclinical | 4 | 2019 | 10 | 0.260 |
Why?
|
| Amino Acid Sequence | 10 | 2013 | 31 | 0.260 |
Why?
|
| Ancylostoma | 2 | 2019 | 2 | 0.250 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2026 | 2 | 0.240 |
Why?
|
| Receptors, Purinergic P2X7 | 1 | 2026 | 2 | 0.240 |
Why?
|
| Xanthones | 1 | 2026 | 1 | 0.240 |
Why?
|
| Organogold Compounds | 1 | 2026 | 1 | 0.240 |
Why?
|
| Albumins | 1 | 2006 | 2 | 0.240 |
Why?
|
| Mefloquine | 1 | 2026 | 1 | 0.240 |
Why?
|
| Inflammation | 1 | 2026 | 31 | 0.240 |
Why?
|
| Thioredoxin Reductase 2 | 1 | 2025 | 1 | 0.240 |
Why?
|
| Female | 9 | 2026 | 1724 | 0.240 |
Why?
|
| Oxidative Stress | 3 | 2025 | 13 | 0.230 |
Why?
|
| Antiparasitic Agents | 2 | 2024 | 2 | 0.230 |
Why?
|
| Cryptosporidiosis | 1 | 2025 | 1 | 0.230 |
Why?
|
| Glutathione Reductase | 2 | 2015 | 2 | 0.220 |
Why?
|
| Prodrugs | 1 | 2024 | 1 | 0.220 |
Why?
|
| Antigens, Helminth | 2 | 2003 | 2 | 0.220 |
Why?
|
| Malaria, Falciparum | 2 | 2013 | 2 | 0.210 |
Why?
|
| Brugia malayi | 2 | 2022 | 2 | 0.210 |
Why?
|
| Onchocerca volvulus | 2 | 2022 | 2 | 0.210 |
Why?
|
| Structure-Activity Relationship | 6 | 2026 | 12 | 0.200 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2023 | 15 | 0.200 |
Why?
|
| Drug Design | 1 | 2013 | 4 | 0.190 |
Why?
|
| Oxadiazoles | 2 | 2014 | 3 | 0.180 |
Why?
|
| Parasites | 1 | 2022 | 1 | 0.180 |
Why?
|
| Plants, Medicinal | 1 | 2022 | 2 | 0.180 |
Why?
|
| Biological Products | 1 | 2022 | 3 | 0.180 |
Why?
|
| B-Lymphocytes | 2 | 2003 | 13 | 0.180 |
Why?
|
| Glutathione Peroxidase | 3 | 2006 | 3 | 0.180 |
Why?
|
| Egg Proteins | 1 | 2001 | 1 | 0.170 |
Why?
|
| Lymphocyte Activation | 1 | 2001 | 6 | 0.170 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2001 | 13 | 0.170 |
Why?
|
| Nanostructures | 1 | 2021 | 4 | 0.170 |
Why?
|
| Proteins | 1 | 2021 | 9 | 0.170 |
Why?
|
| Antiprotozoal Agents | 1 | 2020 | 1 | 0.170 |
Why?
|
| Helminthiasis | 1 | 2020 | 1 | 0.170 |
Why?
|
| Protozoan Infections | 1 | 2020 | 1 | 0.170 |
Why?
|
| Neoplasm Proteins | 1 | 2000 | 3 | 0.160 |
Why?
|
| Neoplasms | 1 | 2020 | 18 | 0.160 |
Why?
|
| Cell Line, Tumor | 3 | 2025 | 23 | 0.150 |
Why?
|
| Molecular Structure | 4 | 2024 | 6 | 0.150 |
Why?
|
| Oviposition | 1 | 2019 | 1 | 0.150 |
Why?
|
| High-Throughput Screening Assays | 1 | 2019 | 1 | 0.150 |
Why?
|
| Helminth Proteins | 2 | 2009 | 2 | 0.150 |
Why?
|
| Gene Expression Regulation | 2 | 2009 | 43 | 0.150 |
Why?
|
| Protein Conformation | 3 | 2013 | 22 | 0.130 |
Why?
|
| Apoptosis | 2 | 2026 | 36 | 0.120 |
Why?
|
| Base Sequence | 6 | 2006 | 24 | 0.120 |
Why?
|
| Hydrogen Peroxide | 3 | 2008 | 4 | 0.120 |
Why?
|
| Male | 5 | 2026 | 1860 | 0.110 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2025 | 6 | 0.110 |
Why?
|
| Cell Proliferation | 2 | 2025 | 25 | 0.110 |
Why?
|
| Glucosephosphate Dehydrogenase Deficiency | 1 | 2015 | 1 | 0.110 |
Why?
|
| Erythrocytes | 1 | 2015 | 6 | 0.110 |
Why?
|
| Elephantiasis, Filarial | 1 | 2015 | 1 | 0.110 |
Why?
|
| Loiasis | 1 | 2015 | 1 | 0.110 |
Why?
|
| Microfilariae | 1 | 2015 | 1 | 0.110 |
Why?
|
| Onchocerciasis | 1 | 2015 | 1 | 0.110 |
Why?
|
| Endothelial Cells | 2 | 2026 | 12 | 0.110 |
Why?
|
| Lung | 2 | 2026 | 18 | 0.110 |
Why?
|
| Praziquantel | 1 | 2014 | 2 | 0.110 |
Why?
|
| Nitric Oxide Donors | 1 | 2014 | 3 | 0.110 |
Why?
|
| Isoquinolines | 1 | 2014 | 5 | 0.110 |
Why?
|
| Pyrazines | 1 | 2014 | 5 | 0.110 |
Why?
|
| Nitric Oxide | 2 | 2014 | 12 | 0.100 |
Why?
|
| Sequence Homology, Amino Acid | 3 | 2012 | 6 | 0.100 |
Why?
|
| Ancylostomiasis | 1 | 2013 | 1 | 0.100 |
Why?
|
| Quinoxalines | 1 | 2013 | 1 | 0.100 |
Why?
|
| Genome, Helminth | 2 | 2012 | 2 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 4 | 2012 | 9 | 0.090 |
Why?
|
| Quinolines | 1 | 2012 | 1 | 0.090 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2012 | 1 | 0.090 |
Why?
|
| Models, Chemical | 1 | 2012 | 23 | 0.090 |
Why?
|
| Cysteine | 3 | 2022 | 3 | 0.090 |
Why?
|
| Cell Line | 3 | 2015 | 56 | 0.080 |
Why?
|
| Mice, Knockout | 2 | 2026 | 67 | 0.080 |
Why?
|
| Antirheumatic Agents | 1 | 2009 | 8 | 0.080 |
Why?
|
| Recombinant Proteins | 3 | 2008 | 57 | 0.080 |
Why?
|
| DNA, Helminth | 3 | 2012 | 3 | 0.080 |
Why?
|
| DNA | 4 | 2009 | 28 | 0.070 |
Why?
|
| Biomphalaria | 1 | 2009 | 1 | 0.070 |
Why?
|
| Disease Models, Animal | 2 | 2026 | 174 | 0.070 |
Why?
|
| Fasciola hepatica | 1 | 2008 | 1 | 0.070 |
Why?
|
| Fascioliasis | 1 | 2008 | 1 | 0.070 |
Why?
|
| Macrophage Activation | 1 | 2008 | 1 | 0.070 |
Why?
|
| Th2 Cells | 1 | 2008 | 1 | 0.070 |
Why?
|
| Macrophages | 1 | 2008 | 13 | 0.070 |
Why?
|
| Cattle | 2 | 2020 | 17 | 0.070 |
Why?
|
| Catalysis | 2 | 2013 | 7 | 0.070 |
Why?
|
| Lipid Peroxidation | 1 | 2006 | 1 | 0.060 |
Why?
|
| Palladium | 1 | 2026 | 1 | 0.060 |
Why?
|
| Antioxidants | 1 | 2006 | 17 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 2 | 2008 | 16 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2025 | 8 | 0.060 |
Why?
|
| Cycloaddition Reaction | 1 | 2024 | 1 | 0.050 |
Why?
|
| Stereoisomerism | 1 | 2024 | 2 | 0.050 |
Why?
|
| Hemoglobins | 1 | 2024 | 3 | 0.050 |
Why?
|
| Drug Discovery | 2 | 2018 | 3 | 0.050 |
Why?
|
| Phylogeny | 3 | 2012 | 4 | 0.050 |
Why?
|
| Caveolin 1 | 1 | 2023 | 1 | 0.050 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type II | 1 | 2023 | 1 | 0.050 |
Why?
|
| Pulmonary Artery | 1 | 2023 | 3 | 0.050 |
Why?
|
| Retroelements | 1 | 2003 | 1 | 0.050 |
Why?
|
| Genome | 1 | 2003 | 2 | 0.050 |
Why?
|
| Antibodies, Helminth | 1 | 2003 | 1 | 0.050 |
Why?
|
| Immunoglobulin A | 1 | 2003 | 1 | 0.050 |
Why?
|
| Schistosoma haematobium | 1 | 2003 | 1 | 0.050 |
Why?
|
| Schistosomiasis haematobia | 1 | 2003 | 1 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2003 | 7 | 0.050 |
Why?
|
| Cloning, Molecular | 4 | 2000 | 6 | 0.050 |
Why?
|
| Reactive Oxygen Species | 2 | 2015 | 23 | 0.050 |
Why?
|
| Selenoproteins | 1 | 2022 | 1 | 0.050 |
Why?
|
| Kenya | 1 | 2022 | 2 | 0.050 |
Why?
|
| Herbal Medicine | 1 | 2022 | 2 | 0.050 |
Why?
|
| Mammals | 1 | 2022 | 6 | 0.050 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2014 | 85 | 0.040 |
Why?
|
| Genes, Helminth | 2 | 2009 | 2 | 0.040 |
Why?
|
| Solubility | 2 | 2012 | 4 | 0.040 |
Why?
|
| Molecular Weight | 1 | 2001 | 5 | 0.040 |
Why?
|
| Mice, Inbred C3H | 1 | 2001 | 6 | 0.040 |
Why?
|
| Biopolymers | 1 | 2021 | 3 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2001 | 32 | 0.040 |
Why?
|
| Sequence Alignment | 2 | 2009 | 2 | 0.040 |
Why?
|
| Drug Evaluation | 1 | 2020 | 2 | 0.040 |
Why?
|
| Expressed Sequence Tags | 1 | 2000 | 1 | 0.040 |
Why?
|
| Precipitin Tests | 1 | 2000 | 2 | 0.040 |
Why?
|
| DNA, Complementary | 1 | 2000 | 5 | 0.040 |
Why?
|
| Blotting, Western | 1 | 2000 | 23 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2001 | 88 | 0.040 |
Why?
|
| Chromosomes, Bacterial | 1 | 2000 | 1 | 0.040 |
Why?
|
| Gene Library | 1 | 2000 | 1 | 0.040 |
Why?
|
| HeLa Cells | 1 | 2019 | 3 | 0.040 |
Why?
|
| Kinetics | 2 | 2009 | 63 | 0.040 |
Why?
|
| Computational Biology | 2 | 2012 | 6 | 0.040 |
Why?
|
| Electrochemistry | 1 | 2015 | 14 | 0.030 |
Why?
|
| In Vitro Techniques | 1 | 2015 | 72 | 0.030 |
Why?
|
| Acetylglucosaminidase | 1 | 1995 | 1 | 0.030 |
Why?
|
| Chitinases | 1 | 1995 | 1 | 0.030 |
Why?
|
| Hexosaminidases | 1 | 1995 | 1 | 0.030 |
Why?
|
| Streptomyces | 1 | 1995 | 1 | 0.030 |
Why?
|
| Benzyl Compounds | 1 | 2015 | 1 | 0.030 |
Why?
|
| Malaria | 1 | 2015 | 1 | 0.030 |
Why?
|
| Vitamin K 3 | 1 | 2015 | 1 | 0.030 |
Why?
|
| Diethylcarbamazine | 1 | 2015 | 1 | 0.030 |
Why?
|
| Filaricides | 1 | 2015 | 1 | 0.030 |
Why?
|
| Gerbillinae | 1 | 2015 | 1 | 0.030 |
Why?
|
| Ivermectin | 1 | 2015 | 1 | 0.030 |
Why?
|
| Loa | 1 | 2015 | 1 | 0.030 |
Why?
|
| Drug Repositioning | 1 | 2015 | 1 | 0.030 |
Why?
|
| Haplorhini | 1 | 2015 | 2 | 0.030 |
Why?
|
| Albendazole | 1 | 2015 | 2 | 0.030 |
Why?
|
| Glutathione Transferase | 1 | 1994 | 2 | 0.030 |
Why?
|
| Isoenzymes | 1 | 1994 | 13 | 0.030 |
Why?
|
| Genetic Variation | 1 | 1994 | 11 | 0.030 |
Why?
|
| Catalytic Domain | 1 | 2013 | 2 | 0.020 |
Why?
|
| Protein Multimerization | 1 | 2013 | 2 | 0.020 |
Why?
|
| Hemin | 1 | 2012 | 1 | 0.020 |
Why?
|
| Methemoglobin | 1 | 2012 | 1 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2012 | 4 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2012 | 10 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2012 | 24 | 0.020 |
Why?
|
| Adult | 1 | 2015 | 794 | 0.020 |
Why?
|
| Peroxidase | 1 | 2012 | 1 | 0.020 |
Why?
|
| Molecular Chaperones | 1 | 2012 | 1 | 0.020 |
Why?
|
| Selenocysteine | 1 | 2011 | 1 | 0.020 |
Why?
|
| Protein Structure, Secondary | 1 | 2011 | 7 | 0.020 |
Why?
|
| Biological Availability | 1 | 2009 | 1 | 0.020 |
Why?
|
| Schistosoma | 1 | 2009 | 1 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2009 | 1 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2009 | 3 | 0.020 |
Why?
|
| Selenium | 1 | 2009 | 1 | 0.020 |
Why?
|
| Protein Structure, Tertiary | 1 | 2009 | 6 | 0.020 |
Why?
|
| Host-Parasite Interactions | 1 | 2009 | 1 | 0.020 |
Why?
|
| Physical Chromosome Mapping | 1 | 2009 | 1 | 0.020 |
Why?
|
| Biological Evolution | 1 | 2009 | 2 | 0.020 |
Why?
|
| Exons | 1 | 2009 | 6 | 0.020 |
Why?
|
| Introns | 1 | 2009 | 6 | 0.020 |
Why?
|
| Rats | 1 | 2009 | 234 | 0.020 |
Why?
|
| Immunization | 1 | 2008 | 1 | 0.020 |
Why?
|
| Interleukin-4 | 1 | 2008 | 1 | 0.020 |
Why?
|
| Interleukin-13 | 1 | 2008 | 1 | 0.020 |
Why?
|
| Immunization, Passive | 1 | 2008 | 2 | 0.020 |
Why?
|
| Antigens, Differentiation | 1 | 2008 | 3 | 0.020 |
Why?
|
| Dithionitrobenzoic Acid | 1 | 2008 | 1 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2008 | 119 | 0.020 |
Why?
|
| Signal Transduction | 1 | 2008 | 97 | 0.020 |
Why?
|
| Nitrosamines | 1 | 2008 | 1 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 1994 | 19 | 0.010 |
Why?
|
| Genomic Library | 1 | 2003 | 1 | 0.010 |
Why?
|
| Chromosomes, Artificial, Bacterial | 1 | 2003 | 1 | 0.010 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2003 | 8 | 0.010 |
Why?
|
| Transcription, Genetic | 1 | 2003 | 11 | 0.010 |
Why?
|
| Parasite Egg Count | 1 | 2003 | 1 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 2003 | 3 | 0.010 |
Why?
|
| Interleukin-10 | 1 | 2003 | 4 | 0.010 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2003 | 11 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2003 | 37 | 0.010 |
Why?
|
| Adolescent | 1 | 2003 | 247 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2000 | 1 | 0.010 |
Why?
|
| Terminal Repeat Sequences | 1 | 2000 | 1 | 0.010 |
Why?
|
| DNA Probes | 1 | 2000 | 2 | 0.010 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 2000 | 2 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2000 | 2 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 2000 | 3 | 0.010 |
Why?
|
| Middle Aged | 1 | 2003 | 792 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1995 | 32 | 0.010 |
Why?
|
| DNA Primers | 1 | 1994 | 12 | 0.010 |
Why?
|
| RNA | 1 | 1994 | 8 | 0.010 |
Why?
|
| DNA, Protozoan | 1 | 1994 | 1 | 0.010 |
Why?
|
| Blotting, Southern | 1 | 1994 | 2 | 0.010 |
Why?
|